Panacea Biotec Ltd

Panacea Biotec Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The upgrade, effective from 07 May 2026, is driven primarily by improvements in technical indicators, while valuation and financial trends remain subdued. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.

Panacea Biotec Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish to a mildly bullish trend on the weekly charts. Despite a modest daily gain of 1.57%, the stock’s technical indicators present a nuanced picture, with some metrics signalling strength while others suggest caution for investors.

The Sensex edged up 0.23% on 6 May 2026, while Panacea Biotec Ltd surged 7.12%, outperforming its Pharmaceuticals & Biotechnology sector by 4.57 percentage points. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, which touched an intraday high of Rs 393.3, marking a notable move within a broader mixed market backdrop.

Panacea Biotec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 31 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

While the Sensex declined by 0.81% on 22 Apr 2026, Panacea Biotec Ltd surged 7.29%, marking a remarkable outperformance of 7.35 percentage points over its Pharmaceuticals & Biotechnology sector. This sharp intraday gain rewrites the short-term narrative for the stock, which had been under pressure in recent sessions.

Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 31 October 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 20 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Panacea Biotec Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade in its Mojo Grade to Strong Sell from Sell, the stock’s price action and technical indicators reveal a landscape of cautious optimism tempered by persistent downside risks.

Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 31 Oct 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 April 2026, providing investors with the latest insights into its performance and outlook.

Panacea Biotec Ltd witnessed a robust start to trading on 1 April 2026, opening with a notable gap up of 6.37%, signalling positive market sentiment despite prevailing bearish technical indicators. The stock outperformed its sector and broader market indices, marking a reversal after three consecutive days of decline.

The Sensex advanced 2.7% on 1 Apr 2026, yet Panacea Biotec Ltd outpaced the broader market with a 7.83% gain, reaching an intraday high of Rs 315. This 3.65-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a mere market lift.

Panacea Biotec Ltd experienced a significant intraday decline on 30 Mar 2026, hitting a new 52-week low of Rs. 293.1 as the stock faced pronounced selling pressure amid broader market weakness and sector underperformance.

For the third consecutive session, Panacea Biotec Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 295.75 on 30 Mar 2026. This marks a significant drop of nearly 50% from its 52-week high of Rs 581, underscoring persistent selling pressure amid a challenging market backdrop.

Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 31 Oct 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 29 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Panacea Biotec Ltd demonstrated robust intraday performance on 18 Mar 2026, surging 7.92% to touch a day’s high of Rs 340.95. This sharp uptick outpaced the broader Sensex, which gained 0.81%, and the Pharmaceuticals & Biotechnology sector, with Panacea Biotec outperforming its sector by 6.76% during the trading session.

Panacea Biotec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Panacea Biotec Ltd recorded a robust intraday performance on 10 Mar 2026, surging to a day’s high of Rs 359.8, marking a 7.47% gain. The stock outpaced the broader market and its sector, reflecting notable trading momentum amid a mixed market backdrop.

Panacea Biotec Ltd commenced trading today with a significant gap up, opening 7.72% higher than its previous close, signalling a robust start amid positive market sentiment. The stock outperformed its sector and broader indices, continuing a short-term upward trajectory following two consecutive days of gains.